149 related articles for article (PubMed ID: 20922580)
1. Clinicopathological significance of macrophage migration inhibitory factor and its relation with p53 in gastric cancer.
Nabizadeh Marvast M; Sima HR; Ghaffarzadehgan K; Taghizadeh Kermani A; Norouzi N
J Gastrointest Cancer; 2011 Mar; 42(1):5-10. PubMed ID: 20922580
[TBL] [Abstract][Full Text] [Related]
2. Expression of macrophage migration inhibitory factor is associated with enhanced angiogenesis and advanced stage in gastric carcinomas.
Shun CT; Lin JT; Huang SP; Lin MT; Wu MS
World J Gastroenterol; 2005 Jun; 11(24):3767-71. PubMed ID: 15968736
[TBL] [Abstract][Full Text] [Related]
3. [Expression and significance of macrophage migration inhibitory factor in gastric adenocarcinoma].
Yu HP; Yu XH; Zhang SX
Zhonghua Yi Xue Za Zhi; 2010 Oct; 90(37):2625-8. PubMed ID: 21162929
[TBL] [Abstract][Full Text] [Related]
4. Macrophage migration inhibitory factor as a potential prognostic factor in gastric cancer.
He LJ; Xie D; Hu PJ; Liao YJ; Deng HX; Kung HF; Zhu SL
World J Gastroenterol; 2015 Sep; 21(34):9916-26. PubMed ID: 26379396
[TBL] [Abstract][Full Text] [Related]
5. CD74 and macrophage migration inhibitory factor as therapeutic targets in gastric cancer.
Zheng YX; Yang M; Rong TT; Yuan XL; Ma YH; Wang ZH; Shen LS; Cui L
World J Gastroenterol; 2012 May; 18(18):2253-61. PubMed ID: 22611320
[TBL] [Abstract][Full Text] [Related]
6. ZFPM2-AS1, a novel lncRNA, attenuates the p53 pathway and promotes gastric carcinogenesis by stabilizing MIF.
Kong F; Deng X; Kong X; Du Y; Li L; Zhu H; Wang Y; Xie D; Guha S; Li Z; Guan M; Xie K
Oncogene; 2018 Nov; 37(45):5982-5996. PubMed ID: 29985481
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of macrophage migration inhibitory factor and DJ-1 contribute to cell invasion and metastasis of nasopharyngeal carcinoma.
Pei XJ; Wu TT; Li B; Tian XY; Li Z; Yang QX
Int J Med Sci; 2014; 11(1):106-15. PubMed ID: 24396292
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological significance of the EMT-related proteins and their interrelationships in prostate cancer. An immunohistochemical study.
Parol-Kulczyk M; Gzil A; Maciejewska J; Bodnar M; Grzanka D
PLoS One; 2021; 16(6):e0253112. PubMed ID: 34157052
[TBL] [Abstract][Full Text] [Related]
9. Increased epithelial and serum expression of macrophage migration inhibitory factor (MIF) in gastric cancer: potential role of MIF in gastric carcinogenesis.
He XX; Yang J; Ding YW; Liu W; Shen QY; Xia HH
Gut; 2006 Jun; 55(6):797-802. PubMed ID: 16488898
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of p53 protein and MK-1 (a tumor-associated antigen) expression in gastric carcinoma.
Deveci MS; Deveci G
Gastric Cancer; 2007; 10(2):112-6. PubMed ID: 17577621
[TBL] [Abstract][Full Text] [Related]
11. P115 promotes growth of gastric cancer through interaction with macrophage migration inhibitory factor.
Li XJ; Luo Y; Yi YF
World J Gastroenterol; 2013 Dec; 19(46):8619-29. PubMed ID: 24379579
[TBL] [Abstract][Full Text] [Related]
12. Expression of p53 protein in Barrett's adenocarcinoma and adenocarcinoma of the gastric cardia and antrum.
Jovanović I; Todorović V; Milosavljević T; Micev M; Pesko P; Bjelović M; Mouzas Y; Tzardi M
Vojnosanit Pregl; 2005 Dec; 62(12):879-85. PubMed ID: 16375215
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine differentiation in gastric adenocarcinomas; correlation with tumor stage and expression of VEGF and p53.
Eren F; Celikel C; Güllüoğlu B
Pathol Oncol Res; 2004; 10(1):47-51. PubMed ID: 15029262
[TBL] [Abstract][Full Text] [Related]
14. [Expression and significance of macrophage migration inhibitory factor in bladder urothelial cell carcinoma].
Guo YS; Dai YP; Li W; Liu LD
Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):28-31. PubMed ID: 21575460
[TBL] [Abstract][Full Text] [Related]
15. Prognostic role of macrophage migration inhibitory factor expression in patients with squamous cell carcinoma of the lung.
Koh HM; Kim DC; Kim YM; Song DH
Thorac Cancer; 2019 Dec; 10(12):2209-2217. PubMed ID: 31602798
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of the p53 tumor suppressor gene product in esophageal and gastric carcinomas.
Fléjou JF; Muzeau F; Potet F; Lepelletier F; Fékété F; Hénin D
Pathol Res Pract; 1994 Dec; 190(12):1141-8. PubMed ID: 7540752
[TBL] [Abstract][Full Text] [Related]
17. [Infection with L-form of Helicobacter pylori and expressions of MIF, MMP9 and VEGF in gastric carcinoma].
Ou Y; Kang M; Zhou L; Cheng Z; Tang S; Yu D
Nan Fang Yi Ke Da Xue Xue Bao; 2014 Feb; 34(2):180-7. PubMed ID: 24589592
[TBL] [Abstract][Full Text] [Related]
18. The immunohistochemical expression of the p53-protein in gastric carcinomas. Correlation with clinicopathological factors and survival of patients.
Lazăr D; Tăban S; Sporea I; Dema A; Cornianu M; Lazăr E; Goldiş A; Raţiu I; Vernic C
Rom J Morphol Embryol; 2010; 51(2):249-57. PubMed ID: 20495739
[TBL] [Abstract][Full Text] [Related]
19. Chemokines mRNA expression in relation to the Macrophage Migration Inhibitory Factor (MIF) mRNA and Vascular Endothelial Growth Factor (VEGF) mRNA expression in the microenvironment of endometrial cancer tissue and normal endometrium: a pilot study.
Giannice R; Erreni M; Allavena P; Buscaglia M; Tozzi R
Cytokine; 2013 Nov; 64(2):509-15. PubMed ID: 23985752
[TBL] [Abstract][Full Text] [Related]
20. MIF family members cooperatively inhibit p53 expression and activity.
Brock SE; Rendon BE; Xin D; Yaddanapudi K; Mitchell RA
PLoS One; 2014; 9(6):e99795. PubMed ID: 24932684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
